Roche has demonstrated the power of combining two of oncology's hottest modalities—bispecifics and antibody-drug conjugates ...

Roche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial for those ...

Roche's Hemlibra treatment for haemophilia A is one of its top-selling drugs, making almost $5 billion last year, and the ...

Novo Nordisk NVO announced new data from the phase III FRONTIER clinical program, comprising five separate studies evaluating ...

In combination with Roche’s PD-L1 blocker Tecentriq, zanzalintinib bested Bayer’s Stivarga. Exelixis is positioning the drug ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive phase I/II data on NXT007 in people with haemophilia A, ...

Shares of Roche drew increased retail attention Monday after the Swiss drugmaker said it would move its investigational ...

The decision to advance prasinezumab to Phase III was based on results from the Phase IIb PADOVA trial, which demonstrated ...

Mathieu Roche discusses the role of identity in digital advertising performance, emphasizing transparent data collection and ...

The commercial and clinical use of Elevidys was discontinued after two fatal cases of acute liver failure.

A suit cannot be maintained under the Civil law, merely based on an apprehension of litigation, without any concrete or ...